Poxviral oncolytic vectors
AssigneeTransgene S.A.
InventorsPhilippe Erbs, Johann Foloppe
Life of this patent
Estimating the term…
Abstract
The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
Claims14
A method for treating cancer, tumors and diseases which result from unwanted cell proliferation comprising administering to a host organism or cell which is in need an oncolytic Orthopox poxvirus comprising a defective I4L and/or a defective F4L gene, and a defective J2R gene, or a composition comprising said poxvirus, with the proviso that said poxvirus is not NYVAC, and administering to said host organism or cell a topoisomerase I inhibitor which is irinotecan.
A method for treating cancer, tumors and diseases which result from unwanted cell proliferation comprising administering to a host organism or cell which is in need an oncolytic Orthopox poxvirus comprising a defective 14L and/or a defective F4L gene and a defective J2R gene or a composition comprising said poxvirus with the proviso that said poxvirus is not NYVAC and further comprising administering to said host organism or cell an antimitotic drug which is oxaliplatin.
Dependencies are inferred from the claim text.